Overview

  • Product name

    Anti-BRCA1 antibody [EPR19433]
    See all BRCA1 primary antibodies
  • Description

    Rabbit monoclonal [EPR19433] to BRCA1
  • Host species

    Rabbit
  • Tested applications

    Suitable for: IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Common marmosetDoes not react with: Mouse
  • Immunogen

    Synthetic peptide within Human BRCA1 aa 1700-1800. The exact sequence is proprietary.
    Database link: P38398

  • Positive control

    • IHC-P: Human breast, breast cancer and ovary cancer tissues. ICC/IF: MCF7 cells.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab213929 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/400. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Perform heat mediated antigen retrieval using Universal HIER antigen retrieval reagent (10X) (ab208572).

ICC/IF 1/1000.

Target

  • Function

    E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
  • Tissue specificity

    Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
  • Pathway

    Protein modification; protein ubiquitination.
  • Involvement in disease

    Defects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
    Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
    Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].
  • Sequence similarities

    Contains 2 BRCT domains.
    Contains 1 RING-type zinc finger.
  • Domain

    The BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
    The RING-type zinc finger domain interacts with BAP1.
  • Post-translational
    modifications

    Phosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
    Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.
  • Cellular localization

    Cytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.
  • Information by UniProt
  • Database links

  • Alternative names

    • BRCA 1 antibody
    • BRCA1 antibody
    • BRCA1 DNA repair associated antibody
    • BRCA1/BRCA2 containing complex subunit 1 antibody
    • BRCA1/BRCA2-containing complex, subunit 1 antibody
    • BRCA1_HUMAN antibody
    • BRCAI antibody
    • BRCC 1 antibody
    • BRCC1 antibody
    • Breast and ovarian cancer susceptibility protein 1 antibody
    • Breast Cancer 1 antibody
    • Breast Cancer 1 Early Onset antibody
    • Breast cancer type 1 susceptibility protein antibody
    • BROVCA1 antibody
    • FANCS antibody
    • IRIS antibody
    • PNCA4 antibody
    • PPP1R53 antibody
    • Protein phosphatase 1 regulatory subunit 53 antibody
    • PSCP antibody
    • RING finger protein 53 antibody
    • RNF53 antibody
    see all

Images

  • Immunohistochemical analysis of paraffin-embedded human breast tissue labeling BRCA1 with ab213929 at 1/400 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). 

    Strong nuclear staining on epithelium cells of human breast is observed.

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized MCF7 (Human breast adenocarcinoma cell line) cells labeling BRCA1 with ab213929 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing nuclear staining on MCF7 cell line. The nuclear counterstain is DAPI (blue).

    Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red).

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

    Negative control: No staining on SUM149PT cell line, which carried the 2288delT mutation of BRCA1 [PMID: 16397213].

  • Immunohistochemical analysis of paraffin-embedded human breast cancer tissue labeling BRCA1 with ab213929 at 1/400 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Lower nuclear staining intensity in tumor cells (left) as compared to its adjacent non-tumor tissue (right).

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Immunohistochemical analysis of paraffin-embedded human breast cancer tissue labeling BRCA1 with ab213929 at 1/400 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Strong nuclear staining on a region of tumor cells from human breast cancer tissue is observed.

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Immunohistochemical analysis of paraffin-embedded human breast cancer tissue labeling BRCA1 with ab213929 at 1/400 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Absent staining on this case of human breast cancer is observed.

    Counter stained with Hematoxylin.

     

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Immunohistochemical analysis of paraffin-embedded human ovary cancer tissue labeling BRCA1 with ab213929 at 1/400 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Strong nuclear staining on a region of tumor cells from human ovary cancer tissue is observed.

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

References

ab213929 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Human Tissue sections (Breast)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: Citric acid
Permeabilization
No
Specification
Breast
Blocking step
BSA as blocking agent for 10 minute(s) · Concentration: 2% · Temperature: 21°C
Fixative
Formaldehyde

Mr. Carl Hobbs

Verified customer

Submitted Aug 20 2018

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up